FDA regulatory rejection risk for D-PLEX100 based on efficacy/safety profile versus existing standard-of-care antibiotic prophylaxis in orthopedic surgery
Reimbursement uncertainty from CMS and private payers for premium-priced local antibiotic delivery systems in cost-conscious healthcare environment
Manufacturing scale-up challenges transitioning from clinical-grade to commercial-scale production of polymer-lipid matrix technology
Patent expiration risk and limited exclusivity period to recoup R&D investment if approval delayed beyond 2028-2030 timeframe
Competing antibiotic-eluting bone void fillers and implant coatings from established orthopedic device companies (Zimmer Biomet, Stryker) with existing surgeon relationships
Systemic antibiotic prophylaxis protocols deeply entrenched in surgical practice with decades of safety data and minimal cost
Larger biotechs with superior capital resources developing rival sustained-release antibiotic platforms
Liquidity crisis risk given zero revenue, negative operating cash flow, and dependence on equity markets for survival - current 1.97x ratio provides limited runway
Severe dilution risk to existing shareholders from future financing rounds at distressed valuations if clinical setbacks occur
Potential inability to raise capital during market downturns or biotech sector selloffs, forcing asset sales or bankruptcy
Negative ROE of -291% and ROA of -153% reflect accumulated losses and capital consumption with no near-term path to profitability
StructuralCompetitiveBalance Sheet
